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pital admission in the next year but paradoxically it also
increased the probability of having zero hospital costs due
to increased risk of death without hospitalization.
CONCLUSIONS: Costs incurred in previous years can be
used to predict costs and outcomes in the future. This dy-
namic three-part model clarifies the relationship between
risk of hospitalization, cost of hospitalization and mortality.
INFECTIOUS DISEASE
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OBJECTIVE: To establish the likely health and cost im-
pacts of a pre-school booster vaccination for Bordetella
pertussis, when added to existing UK primary vaccina-
tion schedules assuming that a diphtheria, tetanus, and
acellular pertussis, (DTPa) booster would replace the cur-
rent diphtheria and tetanus (DT) booster.
METHODS: A transition state model of pertussis infec-
tion in a closed population representative of England and
Wales, comprised of eight age bands with susceptible, in-
fected and immune population sub-groups. Herd-immu-
nity was explicitly modeled. Epidemiological service use
and cost data were sourced from routine statistics, pub-
lished literature and, where necessary, clinical estimates.
The number of pertussis cases, hospitalizations and
deaths were forecast for a five-year period. Quality of life
gains were not explicitly calculated.
RESULTS: Introducing a pre-school pertussis booster
and achieving 84% coverage is predicted to cost an addi-
tional £14.32m over a five-year period, assuming £5
marginal cost between DTPa and DTP or £8.60m assum-
ing a £3 marginal cost. Offset against this are the cost of
reduced hospitalizations and GP consultations, which are
expected to total between £4.21m and £4.60m. The re-
turn on this investment would be a reduction in up to
1700 hospitalizations, between 5000 and 27,000 pertus-
sis cases depending on the level of under-reporting and
assuming a vaccine waning period, and one infant death.
CONCLUSIONS: The introduction of a pre-school
booster is predicted to significantly reduce the number of
hospitalizations and pertussis cases contracted. The esti-
mated marginal cost of this strategy is £10m over a five-
year period, assuming a £5 difference between DTP and
DTPa or £4m, were the difference only £3.
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Viral respiratory infection (VRI) is the most commonly oc-
curring illness in man, imposing considerable burden on
patients and on society. However, to date, no formal study
of the economic impact of VRI has been performed.
OBJECTIVES: To rigorously quantify the economic im-
pact of viral respiratory disease (VRI) in the US in terms
of health-care resource utilization (direct costs) and pro-
ductivity losses (indirect costs).
METHODS: Publicly available databases including the
US Census, National Health Interview Survey (NHIS),
the Medical Expenditure Panel Survey (MEPS) and the
National Ambulatory Medical Care Survey (NAMCS)
were used. From these databases, projections regarding
population characteristics, physician and emergency-room
encounters, prescription and over-the-counter drug utiliza-
tion, and productivity losses related to VRI were made.
Data obtained from primary epidemiological research and
prospective randomized clinical trials were used to esti-
mate the incidence of VRI in the general population and
the rate of secondary clinical complications associated
with VRI.
RESULTS: Nearly 500 million episodes of VRI occur an-
nually in the US alone. Direct costs associated with VRI
are estimated to be $16.8 billion annually and are broken
down as follows: physician visits, $6 billion; complica-
tions, $3.8 billion; prescription and over-the-counter medi-
cations, $4.8 billion. Indirect costs for employed individu-
als approximate $7.6 billion per year. Physician encounters
via a telephone and the internet, productivity losses incurred
by caregivers (i.e. parent) of VRI-infected individuals, and
costs associated with diminished productivity while at work
or home were not included, suggesting that this projection
of total VRI costs—$25 billion annually in the US alone—is
very likely an under-estimate.
CONCLUSIONS: Viral respiratory infections impose a
significant clinical and economic burden to society, ap-
proaching or surpassing the aggregate costs of many
common chronic diseases. The resultant clinical and cost
ramifications attributable to this common acute condi-
tion warrants increased attention from health-care pro-
viders and policy makers.
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OBJECTIVE: Pneumococcal conjugate vaccine for in-
fants has recently been found effective against meningitis,
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bacteremia, pneumonia, and otitis media, but costs more
than previously introduced vaccines. We determined the
savings in medical costs over 36 months of life attribut-
able to the use of the vaccine in healthy infants in a large
randomized trial.
METHODS: We analyzed the actual costs and utilization
for 36,471 children involved in a randomized trial of the
heptavalent pneumococcal conjugate vaccine conducted
in the Northern California Kaiser Permanente Medical
Care Program (KP). Costs were analyzed for all children
randomized in the trial (intent-to-treat) who were mem-
bers of the health plan at any time during the follow-up.
All clinic- and pharmacy-related costs were included, as
were those hospital costs associated with conditions
deemed to be potentially pneumococcal related. The cost
of the vaccine and vaccine administration were excluded.
Confidence intervals around cost savings were calculated
using bootstrap replications.
RESULTS: Compared with the control group, the vacci-
nated group incurred $78 less in medical costs (CI: $5 to
$158) per child during the first 36 months of life, exclu-
sive of the cost of the vaccine. This represented savings of
about 3% of total medical costs for these children during
that time period.
CONCLUSION: The pneumococcal conjugate vaccine
reduced medical costs in children in the first 36 months
of life, before factoring in the cost of the vaccine and vac-
cine administration. These cost savings, however, are un-
likely to offset the cost of the vaccine at its current price.
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OBJECTIVES: To establish the concurrent and discrimi-
natory validity, and relative item importance of the previ-
ously developed client-centered, 51-item Schizophrenia
Outcomes Assessment Project (SOAP-51) survey, a self-
administered, health-related quality of life instrument for
individuals with schizophrenia living in the community.
METHOD: We asked 1500 community-based clients
with schizophrenia, and 150 of their caregivers (using the
shortened objective version), in five ethnically and geo-
graphically diverse areas within the US to complete the
SOAP-51 four times over a three-month period; client re-
tention was 84.2%. Average age was 42.8 years, 60%
males. For concurrent validation, clients rated the impact
of their condition on each of SOAP-51’s eight factors;
this was compared to their factor score. For discriminate
validity, the caregivers assigned clients to one of four
quartiles describing their perception of the client’s ability
to objectively function in each factor area. Client factor
scores were compared to caregiver-reported functional
levels. An additional 300 clients rated the relative impor-
tance of each item.
RESULTS: Cronbach’s alpha for the eight factors was
0.71–0.88, test-retest reliability, 0.78–0.99. Client factor
scores lowered as clients felt the condition had more neg-
atively impacted on their lives (p  .001). Client factor
scores improved with improving caregiver-perceived as-
sessment of client functionality (p  .001). Client scores
from the lowest to highest assigned quartile had average
scores of 42.7%, 49.3%, 54.7%, and 60.0%, respec-
tively. Ninety two percent of both clients and caregivers
considered the survey valuable for monitoring client
progress. No significant difference (p  .05) was ob-
served in importance weights for the eight factors, or 51
items, age or gender of client, caregiver or client re-
sponses.
CONCLUSIONS: Concurrent and discriminatory valid-
ity show that the SOAP-51 meets psychometric charac-
teristics for use as a client-centered outcomes measure in
patient monitoring and management, and health policy
decision-making.
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OBJECTIVES: Because clinical outcomes of depression
treatment in primary care settings tend to be poor, we de-
veloped and evaluated the efficacy of two augmentations
to antidepressant treatment to be delivered by primary
care nurses.
METHODS: We conducted a randomized trial compar-
ing usual care, telehealth care, and telehealth care plus
peer support for depressed patients seen in primary care
in an HMO setting. Assessments were conducted at base-
line, six weeks and six months after study enrollment at
two managed-care, adult primary-care clinics. Partici-
pants included 303 patients recently started on antide-
pressants. The intervention consisted of: telehealth care;
emotional support and focused behavioral interventions
in 10 seven-minute calls over four months by specially
trained primary-care nurses and peer support; telephone
and in-person supportive contacts by trained Health Plan
members recovered from depression. Primary outcome
measures were the Hamilton Rating Scale for Depression,
Beck Depression Inventory, Mental and Physical Func-
tioning (Short Form 12), and treatment satisfaction and
medication adherence questionnaires.
RESULTS: Nurse-based telehealth patients with or with-
out peer support more often experienced 50% improve-
ment on the Hamilton at six weeks (50% vs. 37%, P 
.01) and six months (57% vs. 38%, P  .003), and on
